3Smedby KE, Hjalgrim H. Epidemiology and etiology of mantle cell lym- phoma and other non-Hodgkin lymphoma subtypes[J]. Semin Cancer Biol, 2011,21 (5) : 293-298.
4Vose JM. Mantle cell lymphoma:2012 update on diagnosis,risk-stratifica- tion ,and clinical management[J]. Am J Hemato1,2012,87 (6) :604-609.
5Meggendorfer M, Kern W ,Haferlach C ,et al. SOX11 overexpression is a specific marker for mantle cell lymphoma and correlates with t (11;14) translocation, CCND1 expression and an adverse prognosis[J]. Leukemia, 2013,27(12) :2388-2391.
6Sun T, Nordberg ML, Cotelingam JD, et al. Fluorescence in situ hybridi- zation : method of choice for a definitive diagnosis of mantle cell lympho- ma[J]. Am J Hematol, 2003,74 ( 1 ) : 78-84.
7Yatabe Y ,Suzaki R,Tobinai K,et al. Significance of cyclin D1 overex- pression for the diagnosis of mantle cell lymphoma:a clinicopathologic comparison of cyclin Dl-positive MCL and cyclin Dl-negative MCL-like B-cell lymphoma[J]. Blood, 2000,95 (7) : 2253-2261.
8Fu K, Weisenburger DD, Greiner TC,et al. Cyclin Dl-negative mantle cell lymphoma:a clinicopathologic study based on gene expression profi- ling[J]. Blood, 2005,106 ( 13 ) : 4315-4321.
9Salaverria I,Royo C, Carvajal-Cuenca A,et al. CCND2 rearrangements are the most frequent genetic events in cyclin D1 (-) mantle cell lympho- ma[J]. Blood ,2013,121 (8) : 1394-1402.
10Dreyling M ,Thieblemont C, Gallamini A, et al. ESMO Consensus confer- ences : guidelines on malignant lymphoma, part 2 : marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma[J]. Ann Oncol, 2013, 24(4) :857-877.
